Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.
Clinical Professor of Shanghai Tongji Hospital
To establish a genotyping and extraction technology of non invasive prenatal diagnosis for fetal blood group genotype from cell-free fetal DNA in peripheral blood of pregnant women.
To achieve prenatal accurate identification of fetal blood group genotypes，and provide credible theoretical evidence for the prenatal diagnosis and treatment of hemolytic disease of newborn (HDN).
Study Overview
Detailed Description
Study Type
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
blood samples of pregnant couples,gender/nation/region is unlimited.
Exclusion Criteria:
adipose or hemolytic samples,overdue samples,unidentified samples
Study Plan
How is the study designed?
Collaborators and Investigators
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- ShangjiTongjiHsxk
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HDFN
-
Janssen Research & Development, LLCCompletedErythroblastosis, Fetal | Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN)United States, Canada, Netherlands, Belgium, Australia, Germany, Spain, Sweden, United Kingdom